Hanson & Doremus Investment Management Has $853,000 Stock Position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Share on StockTwits

Hanson & Doremus Investment Management decreased its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 14.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,577 shares of the financial services provider’s stock after selling 1,475 shares during the quarter. Hanson & Doremus Investment Management’s holdings in iShares Nasdaq Biotechnology ETF were worth $853,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Clearbridge Investments LLC lifted its holdings in iShares Nasdaq Biotechnology ETF by 1,392.9% in the first quarter. Clearbridge Investments LLC now owns 5,225 shares of the financial services provider’s stock valued at $584,000 after acquiring an additional 4,875 shares during the period. Great Valley Advisor Group Inc. lifted its position in iShares Nasdaq Biotechnology ETF by 26.4% during the 2nd quarter. Great Valley Advisor Group Inc. now owns 2,271 shares of the financial services provider’s stock worth $248,000 after acquiring an additional 475 shares in the last quarter. Cetera Advisor Networks LLC lifted its position in iShares Nasdaq Biotechnology ETF by 0.3% during the 2nd quarter. Cetera Advisor Networks LLC now owns 57,742 shares of the financial services provider’s stock worth $6,301,000 after acquiring an additional 199 shares in the last quarter. Bangor Savings Bank acquired a new position in iShares Nasdaq Biotechnology ETF during the 2nd quarter worth approximately $1,417,000. Finally, Essex Savings Bank lifted its position in iShares Nasdaq Biotechnology ETF by 114.1% during the 2nd quarter. Essex Savings Bank now owns 4,503 shares of the financial services provider’s stock worth $491,000 after acquiring an additional 2,400 shares in the last quarter. 79.34% of the stock is currently owned by hedge funds and other institutional investors.

iShares Nasdaq Biotechnology ETF stock traded up $2.01 during midday trading on Friday, hitting $110.36. 1,611,700 shares of the company were exchanged, compared to its average volume of 2,375,580. The company’s fifty day moving average price is $103.43 and its 200-day moving average price is $104.61. iShares Nasdaq Biotechnology ETF has a fifty-two week low of $89.01 and a fifty-two week high of $116.25.

Separately, ValuEngine lowered iShares Nasdaq Biotechnology ETF from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: Why do analysts give a neutral rating?

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.